MedPath

Afexa Life Sciences Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:3
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
2 (40.0%)

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

Phase 1
Terminated
Conditions
Impaired Glucose Tolerance
First Posted Date
2011-11-09
Last Posted Date
2012-01-31
Lead Sponsor
Afexa Life Sciences Inc
Target Recruit Count
17
Registration Number
NCT01468376
Locations
🇺🇸

Staywell Research LLC, Northridge, California, United States

Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

Phase 1
Withdrawn
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
First Posted Date
2011-10-20
Last Posted Date
2012-01-25
Lead Sponsor
Afexa Life Sciences Inc
Registration Number
NCT01456182
Locations
🇺🇸

Saint Jospeh Mercy Health System, Ann Arbor, Michigan, United States

🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

Cancer Center of the Carolinas, Greenville, South Carolina, United States

A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population

Phase 2
Completed
Conditions
Upper Respiratory Tract Infections
First Posted Date
2009-08-26
Last Posted Date
2012-08-31
Lead Sponsor
Afexa Life Sciences Inc
Target Recruit Count
293
Registration Number
NCT00965822
Locations
🇨🇦

Alberta Health Services, Edmonton, Alberta, Canada

🇨🇦

Saint John Regional Hospital, Saint John, New Brunswick, Canada

🇨🇦

Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada

and more 1 locations

LIP-01 in Hypercholesterolemia

Phase 1
Completed
Conditions
Hypercholesterolemia
First Posted Date
2009-08-26
Last Posted Date
2012-01-31
Lead Sponsor
Afexa Life Sciences Inc
Target Recruit Count
40
Registration Number
NCT00966225
Locations
🇺🇸

Medicus Research, LLC, Northridge, California, United States

🇨🇦

The Northern Alberta Clinical Trials and Research Centre, Edmonton, Alberta, Canada

A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis

Phase 2
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2008-07-31
Last Posted Date
2010-10-11
Lead Sponsor
Afexa Life Sciences Inc
Target Recruit Count
200
Registration Number
NCT00726401
Locations
🇨🇦

Capital Health, Edmonton, Alberta, Canada

🇨🇦

McMaster University Medical Centre, Hamilton, Ontario, Canada

🇨🇦

Melimar Allergy Laboratory, Toronto, Ontario, Canada

and more 1 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath